Kyverna Therapeutics, Inc. Share Price

Equities

KYTX

US5019761049

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 28/05/2024 BST 5-day change 1st Jan Change
13.23 USD +1.77% Intraday chart for Kyverna Therapeutics, Inc. -3.43% 0.00%
Sales 2024 * 3.75M 294M Sales 2025 * 5M 392M Capitalization 570M 44.74B
Net income 2024 * -138M -10.82B Net income 2025 * -197M -15.45B EV / Sales 2024 * 99.9 x
Net cash position 2024 * 196M 15.35B Net cash position 2025 * 138M 10.85B EV / Sales 2025 * 86.4 x
P/E ratio 2024 *
-3.67 x
P/E ratio 2025 *
-3.12 x
Employees 96
Yield 2024 *
-
Yield 2025 *
-
Free-Float 89.27%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.77%
1 week-3.43%
Current month-12.62%
1 month-14.48%
3 months-52.87%
More quotes
1 week
12.15
Extreme 12.15
13.72
1 month
12.15
Extreme 12.15
17.55
Current year
12.15
Extreme 12.15
35.06
1 year
12.15
Extreme 12.15
35.06
3 years
12.15
Extreme 12.15
35.06
5 years
12.15
Extreme 12.15
35.06
10 years
12.15
Extreme 12.15
35.06
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 12/10/22
Director of Finance/CFO 36 31/12/17
Chief Tech/Sci/R&D Officer 61 31/12/19
Members of the board TitleAgeSince
Director/Board Member 67 31/08/18
Chairman 62 14/09/21
Director/Board Member 65 31/03/21
More insiders
Date Price Change Volume
28/05/24 13.23 +1.77% 404,360
24/05/24 13 +4.59% 192,988
23/05/24 12.43 -6.75% 231,719
22/05/24 13.33 -2.70% 192,931
21/05/24 13.7 -4.86% 321,711

Delayed Quote Nasdaq, May 28, 2024 at 09:00 pm

More quotes
Kyverna Therapeutics, Inc. is a patient-centered, clinical-stage biopharmaceutical company. The Company is focused on developing cell therapies for patients suffering from autoimmune diseases. The Company's lead program, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor (CAR). It intends to develop KYV-101 in two areas of autoimmune disease: rheumatology and neurology. Its initial rheumatology development focus is on lupus nephritis, and systemic sclerosis. It is also actively developing an allogeneic, off-the-shelf approach to further broaden patient access. Its research-stage programs are focused on developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, and extend beyond CD19 CAR-T approaches, including regulatory T cells, or T-regs, and novel humanized CAR constructs developed by it for use in autoimmune diseases.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.23 USD
Average target price
42.75 USD
Spread / Average Target
+223.13%
Consensus